際際滷shows by User: OnQHealth / http://www.slideshare.net/images/logo.gif 際際滷shows by User: OnQHealth / Wed, 11 Jan 2023 20:42:52 GMT 際際滷Share feed for 際際滷shows by User: OnQHealth Predictors of Symptom Worsening or Improvement using Remote Patient Reported Outcomes (PRO) Technology /slideshow/predictors-of-symptom-worsening-or-improvement-using-remote-patient-reported-outcomes-pro-technology/255287933 ispor22podiumpresentation002-230111204252-6cc805a6
Carevive ISPOR 22 Podium Presentation]]>
Carevive ISPOR 22 Podium Presentation]]> Wed, 11 Jan 2023 20:42:52 GMT /slideshow/predictors-of-symptom-worsening-or-improvement-using-remote-patient-reported-outcomes-pro-technology/255287933 OnQHealth@slideshare.net(OnQHealth) Predictors of Symptom Worsening or Improvement using Remote Patient Reported Outcomes (PRO) Technology OnQHealth Carevive ISPOR 22 Podium Presentation <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ispor22podiumpresentation002-230111204252-6cc805a6-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Carevive ISPOR 22 Podium Presentation
Predictors of Symptom Worsening or Improvement using Remote Patient Reported Outcomes (PRO) Technology from Carevive
]]> 59 0 https://cdn.slidesharecdn.com/ss_thumbnails/ispor22podiumpresentation002-230111204252-6cc805a6-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 AMCCBS Virtual鐃2021 Conference Takeaways Part 2 /OnQHealth/amccbs-virtual2021-conference-takeaways-part-2-245922659 keytakeawaysdebamccbsvirtual-210408155710
Check out Debra Wujcik's takeaways from her presentation at #AMCCBSVirtual. She talked about the benefits and crucial data that can be harnessed when using Remote Symptom Monitoring and ePRO platforms.]]>
Check out Debra Wujcik's takeaways from her presentation at #AMCCBSVirtual. She talked about the benefits and crucial data that can be harnessed when using Remote Symptom Monitoring and ePRO platforms.]]> Thu, 08 Apr 2021 15:57:09 GMT /OnQHealth/amccbs-virtual2021-conference-takeaways-part-2-245922659 OnQHealth@slideshare.net(OnQHealth) AMCCBS Virtual鐃2021 Conference Takeaways Part 2 OnQHealth Check out Debra Wujcik's takeaways from her presentation at #AMCCBSVirtual. She talked about the benefits and crucial data that can be harnessed when using Remote Symptom Monitoring and ePRO platforms. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/keytakeawaysdebamccbsvirtual-210408155710-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Check out Debra Wujcik&#39;s takeaways from her presentation at #AMCCBSVirtual. She talked about the benefits and crucial data that can be harnessed when using Remote Symptom Monitoring and ePRO platforms.
AMCCBS Virtual 2021 Conference Takeaways Part 2 from Carevive
]]> 106 0 https://cdn.slidesharecdn.com/ss_thumbnails/keytakeawaysdebamccbsvirtual-210408155710-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 AMCCBS Virtual鐃2021 Conference Takeaways Part 1 /slideshow/amccbs-virtual2021-conference-takeaways-part-1/245818891 keytakeawaysamccbsvirtual-210407012735
Takeaways from Carevive's March 2nd presentation featuring Ethan Basch, Madelyn Trupkin Herzfeld, Bruno Lempernesse, and Nadia Still DNP, RN. Learn more about Carevive's breakthrough cancer care platform: https://bit.ly/3bJ5H1z]]>
Takeaways from Carevive's March 2nd presentation featuring Ethan Basch, Madelyn Trupkin Herzfeld, Bruno Lempernesse, and Nadia Still DNP, RN. Learn more about Carevive's breakthrough cancer care platform: https://bit.ly/3bJ5H1z]]> Wed, 07 Apr 2021 01:27:34 GMT /slideshow/amccbs-virtual2021-conference-takeaways-part-1/245818891 OnQHealth@slideshare.net(OnQHealth) AMCCBS Virtual鐃2021 Conference Takeaways Part 1 OnQHealth Takeaways from Carevive's March 2nd presentation featuring Ethan Basch, Madelyn Trupkin Herzfeld, Bruno Lempernesse, and Nadia Still DNP, RN. Learn more about Carevive's breakthrough cancer care platform: https://bit.ly/3bJ5H1z <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/keytakeawaysamccbsvirtual-210407012735-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Takeaways from Carevive&#39;s March 2nd presentation featuring Ethan Basch, Madelyn Trupkin Herzfeld, Bruno Lempernesse, and Nadia Still DNP, RN. Learn more about Carevive&#39;s breakthrough cancer care platform: https://bit.ly/3bJ5H1z
AMCCBS Virtual 2021 Conference Takeaways Part 1 from Carevive
]]> 133 0 https://cdn.slidesharecdn.com/ss_thumbnails/keytakeawaysamccbsvirtual-210407012735-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Whats New in Acute Myelogenous Leukemia? /slideshow/whats-new-in-acute-myelogenous-leukemia/134915828 422-aml-leblanc-monograph-190306152403
For full accreditation info click here: https://www.carevive.com/whats-new-in-acute-myelogenous-leukemia/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.L. Target Audience This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). Educational Objectives At the conclusion of these educational initiatives, participants should be able to: Assess clinical data on newly approved agents for relapsed/refractory AML Select appropriate treatment for AML according to patient risk group Integrate evidence-based guidelines into practice to treat patients with AML guided by molecular and cytogenetic and testing and patient-specific characteristics Faculty Thomas W. LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute]]>
For full accreditation info click here: https://www.carevive.com/whats-new-in-acute-myelogenous-leukemia/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.L. Target Audience This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). Educational Objectives At the conclusion of these educational initiatives, participants should be able to: Assess clinical data on newly approved agents for relapsed/refractory AML Select appropriate treatment for AML according to patient risk group Integrate evidence-based guidelines into practice to treat patients with AML guided by molecular and cytogenetic and testing and patient-specific characteristics Faculty Thomas W. LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute]]> Wed, 06 Mar 2019 15:24:03 GMT /slideshow/whats-new-in-acute-myelogenous-leukemia/134915828 OnQHealth@slideshare.net(OnQHealth) Whats New in Acute Myelogenous Leukemia? OnQHealth For full accreditation info click here: https://www.carevive.com/whats-new-in-acute-myelogenous-leukemia/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.L. Target Audience This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). Educational Objectives At the conclusion of these educational initiatives, participants should be able to: Assess clinical data on newly approved agents for relapsed/refractory AML Select appropriate treatment for AML according to patient risk group Integrate evidence-based guidelines into practice to treat patients with AML guided by molecular and cytogenetic and testing and patient-specific characteristics Faculty Thomas W. LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/422-aml-leblanc-monograph-190306152403-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> For full accreditation info click here: https://www.carevive.com/whats-new-in-acute-myelogenous-leukemia/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.L. Target Audience This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). Educational Objectives At the conclusion of these educational initiatives, participants should be able to: Assess clinical data on newly approved agents for relapsed/refractory AML Select appropriate treatment for AML according to patient risk group Integrate evidence-based guidelines into practice to treat patients with AML guided by molecular and cytogenetic and testing and patient-specific characteristics Faculty Thomas W. LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute
Whats New in Acute Myelogenous Leukemia? from Carevive
]]> 157 4 https://cdn.slidesharecdn.com/ss_thumbnails/422-aml-leblanc-monograph-190306152403-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Geriatric Assessment in Older Patients with Acute Myelogenous Leukemia: Treatment Updates and Implications /slideshow/geriatric-assessment-in-older-patients-with-acute-myelogenous-leukemia-treatment-updates-and-implications/134915826 422-aml-bryant-monograph-190306152403
For full accreditation info click here: https://www.carevive.com/geriatric-assessment-in-older-patients-with-aml-treatment-updates-and-implications/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML TARGET AUDIENCE This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). EDUCATIONAL OBJECTIVES At the conclusion of these educational initiatives, participants should be able to: Select appropriate treatment for AML according to patient risk group Assess frailty status among older patients newly diagnosed with AML or those needing a new line of therapy FACULTY Ashley Leak Bryant, PhD, RN-BC, OCN University of North Carolina Lineberger Comprehensive Cancer Center]]>
For full accreditation info click here: https://www.carevive.com/geriatric-assessment-in-older-patients-with-aml-treatment-updates-and-implications/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML TARGET AUDIENCE This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). EDUCATIONAL OBJECTIVES At the conclusion of these educational initiatives, participants should be able to: Select appropriate treatment for AML according to patient risk group Assess frailty status among older patients newly diagnosed with AML or those needing a new line of therapy FACULTY Ashley Leak Bryant, PhD, RN-BC, OCN University of North Carolina Lineberger Comprehensive Cancer Center]]> Wed, 06 Mar 2019 15:24:03 GMT /slideshow/geriatric-assessment-in-older-patients-with-acute-myelogenous-leukemia-treatment-updates-and-implications/134915826 OnQHealth@slideshare.net(OnQHealth) Geriatric Assessment in Older Patients with Acute Myelogenous Leukemia: Treatment Updates and Implications OnQHealth For full accreditation info click here: https://www.carevive.com/geriatric-assessment-in-older-patients-with-aml-treatment-updates-and-implications/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML TARGET AUDIENCE This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). EDUCATIONAL OBJECTIVES At the conclusion of these educational initiatives, participants should be able to: Select appropriate treatment for AML according to patient risk group Assess frailty status among older patients newly diagnosed with AML or those needing a new line of therapy FACULTY Ashley Leak Bryant, PhD, RN-BC, OCN University of North Carolina Lineberger Comprehensive Cancer Center <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/422-aml-bryant-monograph-190306152403-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> For full accreditation info click here: https://www.carevive.com/geriatric-assessment-in-older-patients-with-aml-treatment-updates-and-implications/ Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML TARGET AUDIENCE This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML). EDUCATIONAL OBJECTIVES At the conclusion of these educational initiatives, participants should be able to: Select appropriate treatment for AML according to patient risk group Assess frailty status among older patients newly diagnosed with AML or those needing a new line of therapy FACULTY Ashley Leak Bryant, PhD, RN-BC, OCN University of North Carolina Lineberger Comprehensive Cancer Center
Geriatric Assessment in Older Patients with Acute Myelogenous Leukemia: Treatment Updates and Implications from Carevive
]]> 134 3 https://cdn.slidesharecdn.com/ss_thumbnails/422-aml-bryant-monograph-190306152403-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) /slideshow/improving-management-of-nonmetastatic-castrationresistant-prostate-cancer-nmcrpc/132234562 428nmcrpcfinal-190218140223
NOT FOR CME - FOR REFERENCE ONLY In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016). Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016). Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.]]>
NOT FOR CME - FOR REFERENCE ONLY In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016). Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016). Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.]]> Mon, 18 Feb 2019 14:02:23 GMT /slideshow/improving-management-of-nonmetastatic-castrationresistant-prostate-cancer-nmcrpc/132234562 OnQHealth@slideshare.net(OnQHealth) Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) OnQHealth NOT FOR CME - FOR REFERENCE ONLY In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016). Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016). Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/428nmcrpcfinal-190218140223-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> NOT FOR CME - FOR REFERENCE ONLY In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) &gt;8 years and a median overall survival (OS) of &gt;23 years (Rozet et al., 2016). Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016). Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.
Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) from Carevive
]]> 508 7 https://cdn.slidesharecdn.com/ss_thumbnails/428nmcrpcfinal-190218140223-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Defining What is Value-Based Care for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia /slideshow/defining-what-is-valuebased-care-for-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia/104571548 411clldownloadableslides-180706174748
The target audiences for these activities are hematologists, medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, registered nurses, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with chronic lymphocytic leukemia (CLL) and quality administrators responsible for their cancer centers adherence to value-based care delivery models.]]>
The target audiences for these activities are hematologists, medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, registered nurses, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with chronic lymphocytic leukemia (CLL) and quality administrators responsible for their cancer centers adherence to value-based care delivery models.]]> Fri, 06 Jul 2018 17:47:47 GMT /slideshow/defining-what-is-valuebased-care-for-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia/104571548 OnQHealth@slideshare.net(OnQHealth) Defining What is Value-Based Care for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia OnQHealth The target audiences for these activities are hematologists, medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, registered nurses, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with chronic lymphocytic leukemia (CLL) and quality administrators responsible for their cancer centers adherence to value-based care delivery models. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/411clldownloadableslides-180706174748-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The target audiences for these activities are hematologists, medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, registered nurses, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with chronic lymphocytic leukemia (CLL) and quality administrators responsible for their cancer centers adherence to value-based care delivery models.
Defining What is Value-Based Care for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia from Carevive
]]> 282 6 https://cdn.slidesharecdn.com/ss_thumbnails/411clldownloadableslides-180706174748-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia /slideshow/evidencebased-clinical-updates-in-the-treatment-of-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia/76949561 cllepromanuscriptsfinal-170614194513
For information about AMA PRA Category 2 CreditTM, you may consult page 10 of the AMAs booklet The Physicians Recognition Award and credit system: Information for accredited providers and physicians 2010 Revision found at the following link https://www. ama-assn.org/sites/default/files/media-browser/public/ cme/pra-booklet_0.pdf]]>
For information about AMA PRA Category 2 CreditTM, you may consult page 10 of the AMAs booklet The Physicians Recognition Award and credit system: Information for accredited providers and physicians 2010 Revision found at the following link https://www. ama-assn.org/sites/default/files/media-browser/public/ cme/pra-booklet_0.pdf]]> Wed, 14 Jun 2017 19:45:13 GMT /slideshow/evidencebased-clinical-updates-in-the-treatment-of-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia/76949561 OnQHealth@slideshare.net(OnQHealth) Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia OnQHealth For information about AMA PRA Category 2 CreditTM, you may consult page 10 of the AMAs booklet The Physicians Recognition Award and credit system: Information for accredited providers and physicians 2010 Revision found at the following link https://www. ama-assn.org/sites/default/files/media-browser/public/ cme/pra-booklet_0.pdf <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cllepromanuscriptsfinal-170614194513-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> For information about AMA PRA Category 2 CreditTM, you may consult page 10 of the AMAs booklet The Physicians Recognition Award and credit system: Information for accredited providers and physicians 2010 Revision found at the following link https://www. ama-assn.org/sites/default/files/media-browser/public/ cme/pra-booklet_0.pdf
Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia from Carevive
]]> 783 11 https://cdn.slidesharecdn.com/ss_thumbnails/cllepromanuscriptsfinal-170614194513-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Carevive featured in Advisory Board Company Oncology Rountable /slideshow/carevive-featured-in-advisory-board-company-oncology-rountable/75278791 carevivenationalmeetingslides2017-170421123517
Make Advance Care Planning a Critical Component resulted in increased physician adherence to QOPI metrics.]]>
Make Advance Care Planning a Critical Component resulted in increased physician adherence to QOPI metrics.]]> Fri, 21 Apr 2017 12:35:17 GMT /slideshow/carevive-featured-in-advisory-board-company-oncology-rountable/75278791 OnQHealth@slideshare.net(OnQHealth) Carevive featured in Advisory Board Company Oncology Rountable OnQHealth Make Advance Care Planning a Critical Component resulted in increased physician adherence to QOPI metrics. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/carevivenationalmeetingslides2017-170421123517-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Make Advance Care Planning a Critical Component resulted in increased physician adherence to QOPI metrics.
Carevive featured in Advisory Board Company Oncology Rountable from Carevive
]]> 887 7 https://cdn.slidesharecdn.com/ss_thumbnails/carevivenationalmeetingslides2017-170421123517-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Survivorship Care and Care Plans: Transforming Challenges into Opportunities /slideshow/survivorship-care-and-care-plans-transforming-challenges-into-opportunities-59932487/59932487 strickerscpschallengoppty3-160323123414
Updated March 2016. Dr. Carrie Stricker's recent survivorship presentation at the University of Kansas Medical Center. ]]>
Updated March 2016. Dr. Carrie Stricker's recent survivorship presentation at the University of Kansas Medical Center. ]]> Wed, 23 Mar 2016 12:34:14 GMT /slideshow/survivorship-care-and-care-plans-transforming-challenges-into-opportunities-59932487/59932487 OnQHealth@slideshare.net(OnQHealth) Survivorship Care and Care Plans: Transforming Challenges into Opportunities OnQHealth Updated March 2016. Dr. Carrie Stricker's recent survivorship presentation at the University of Kansas Medical Center. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/strickerscpschallengoppty3-160323123414-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Updated March 2016. Dr. Carrie Stricker&#39;s recent survivorship presentation at the University of Kansas Medical Center.
Survivorship Care and Care Plans: Transforming Challenges into Opportunities from Carevive
]]> 1683 13 https://cdn.slidesharecdn.com/ss_thumbnails/strickerscpschallengoppty3-160323123414-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Cancer Survivorship Care: 鐃Global Perspectives and Opportunities for Nurse-Led Care鐃 /slideshow/cancer-survivorship-care-global-perspectives-and-opportunities-for-nurseled-care/50766162 strickeraustraliaspcglobalperspectives-150721155741-lva1-app6892
The 18th CNSA Annual Winter Congress, held Perth, Australia will featured On Q Healths co-founder Dr. Carrie Stricker as a keynote speaker. The theme for this years edition is Cancer Nursing: Expanding the Possibilities and will focus on exploring the opportunities that exist in cancer nursing in 2015 and beyond.]]>
The 18th CNSA Annual Winter Congress, held Perth, Australia will featured On Q Healths co-founder Dr. Carrie Stricker as a keynote speaker. The theme for this years edition is Cancer Nursing: Expanding the Possibilities and will focus on exploring the opportunities that exist in cancer nursing in 2015 and beyond.]]> Tue, 21 Jul 2015 15:57:41 GMT /slideshow/cancer-survivorship-care-global-perspectives-and-opportunities-for-nurseled-care/50766162 OnQHealth@slideshare.net(OnQHealth) Cancer Survivorship Care: 鐃Global Perspectives and Opportunities for Nurse-Led Care鐃 OnQHealth The 18th CNSA Annual Winter Congress, held Perth, Australia will featured On Q Healths co-founder Dr. Carrie Stricker as a keynote speaker. The theme for this years edition is Cancer Nursing: Expanding the Possibilities and will focus on exploring the opportunities that exist in cancer nursing in 2015 and beyond. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/strickeraustraliaspcglobalperspectives-150721155741-lva1-app6892-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The 18th CNSA Annual Winter Congress, held Perth, Australia will featured On Q Healths co-founder Dr. Carrie Stricker as a keynote speaker. The theme for this years edition is Cancer Nursing: Expanding the Possibilities and will focus on exploring the opportunities that exist in cancer nursing in 2015 and beyond.
Cancer Survivorship Care: Global Perspectives and Opportunities for Nurse-Led Care from Carevive
]]> 953 9 https://cdn.slidesharecdn.com/ss_thumbnails/strickeraustraliaspcglobalperspectives-150721155741-lva1-app6892-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Survivorship Care and Care Plans: Transforming Challenges into Opportunities /slideshow/survivorship-care-and-care-plans-transforming-challenges-into-opportunities/49568466 strickeretalscpsintheusarizonaccv3-150618183604-lva1-app6891
Dr. Carrie Stricker attended last month's Arizona Cancer Survivorship Care Plan Summit in Phoenix Arizona. The summit was a joint effort between the Arizona Cancer Coalition , the Arizona Department of Health Services, and the Susan G. Komen速 Central and Northern Arizona. Comprehensive Cancer Control (CCC) Programs work in their community to promote healthy lifestyles and recommended cancer screening, educate people about cancer symptoms, increase access to quality cancer care, and enhance cancer survivors' quality of care. The Arizona Department of Health Services developed the Arizona Cancer Coalition for dedicated individuals, professionals, and cancer survivors to address the priorities outlined in the Arizona Cancer Control Plan. These priorities include prevent cancer, detect cancer early, elevate cancer treatment, galvanize quality of life/survivorship care networks, and catalyze research. Susan G. Kamen速 Central and Northern Arizona is one of 120 Affiliates around the world dedicated to combating breast cancer at every front. Its service area encompasses all of central and northern Arizona, including Apache, Coconino, Gila, La Paz, Maricopa, Mohave, Navajo, Pinal and Yavapai counties. Through events like the Susan G. Kamen Phoenix Race for the Cure速, the Affiliate has invested more than $26.4 million in local breast health and breast cancer awareness projects in central and northern Arizona, and breast cancer research. This summit served as a forum for clinicians, nurses, program planners, and public health professionals within Commission on Cancer (CoC) accredited hospitals to learn about survivorship care plans and address the implementation of standard 3.3 of CoC accreditation.]]>
Dr. Carrie Stricker attended last month's Arizona Cancer Survivorship Care Plan Summit in Phoenix Arizona. The summit was a joint effort between the Arizona Cancer Coalition , the Arizona Department of Health Services, and the Susan G. Komen速 Central and Northern Arizona. Comprehensive Cancer Control (CCC) Programs work in their community to promote healthy lifestyles and recommended cancer screening, educate people about cancer symptoms, increase access to quality cancer care, and enhance cancer survivors' quality of care. The Arizona Department of Health Services developed the Arizona Cancer Coalition for dedicated individuals, professionals, and cancer survivors to address the priorities outlined in the Arizona Cancer Control Plan. These priorities include prevent cancer, detect cancer early, elevate cancer treatment, galvanize quality of life/survivorship care networks, and catalyze research. Susan G. Kamen速 Central and Northern Arizona is one of 120 Affiliates around the world dedicated to combating breast cancer at every front. Its service area encompasses all of central and northern Arizona, including Apache, Coconino, Gila, La Paz, Maricopa, Mohave, Navajo, Pinal and Yavapai counties. Through events like the Susan G. Kamen Phoenix Race for the Cure速, the Affiliate has invested more than $26.4 million in local breast health and breast cancer awareness projects in central and northern Arizona, and breast cancer research. This summit served as a forum for clinicians, nurses, program planners, and public health professionals within Commission on Cancer (CoC) accredited hospitals to learn about survivorship care plans and address the implementation of standard 3.3 of CoC accreditation.]]> Thu, 18 Jun 2015 18:36:04 GMT /slideshow/survivorship-care-and-care-plans-transforming-challenges-into-opportunities/49568466 OnQHealth@slideshare.net(OnQHealth) Survivorship Care and Care Plans: Transforming Challenges into Opportunities OnQHealth Dr. Carrie Stricker attended last month's Arizona Cancer Survivorship Care Plan Summit in Phoenix Arizona. The summit was a joint effort between the Arizona Cancer Coalition , the Arizona Department of Health Services, and the Susan G. Komen速 Central and Northern Arizona. Comprehensive Cancer Control (CCC) Programs work in their community to promote healthy lifestyles and recommended cancer screening, educate people about cancer symptoms, increase access to quality cancer care, and enhance cancer survivors' quality of care. The Arizona Department of Health Services developed the Arizona Cancer Coalition for dedicated individuals, professionals, and cancer survivors to address the priorities outlined in the Arizona Cancer Control Plan. These priorities include prevent cancer, detect cancer early, elevate cancer treatment, galvanize quality of life/survivorship care networks, and catalyze research. Susan G. Kamen速 Central and Northern Arizona is one of 120 Affiliates around the world dedicated to combating breast cancer at every front. Its service area encompasses all of central and northern Arizona, including Apache, Coconino, Gila, La Paz, Maricopa, Mohave, Navajo, Pinal and Yavapai counties. Through events like the Susan G. Kamen Phoenix Race for the Cure速, the Affiliate has invested more than $26.4 million in local breast health and breast cancer awareness projects in central and northern Arizona, and breast cancer research. This summit served as a forum for clinicians, nurses, program planners, and public health professionals within Commission on Cancer (CoC) accredited hospitals to learn about survivorship care plans and address the implementation of standard 3.3 of CoC accreditation. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/strickeretalscpsintheusarizonaccv3-150618183604-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Carrie Stricker attended last month&#39;s Arizona Cancer Survivorship Care Plan Summit in Phoenix Arizona. The summit was a joint effort between the Arizona Cancer Coalition , the Arizona Department of Health Services, and the Susan G. Komen速 Central and Northern Arizona. Comprehensive Cancer Control (CCC) Programs work in their community to promote healthy lifestyles and recommended cancer screening, educate people about cancer symptoms, increase access to quality cancer care, and enhance cancer survivors&#39; quality of care. The Arizona Department of Health Services developed the Arizona Cancer Coalition for dedicated individuals, professionals, and cancer survivors to address the priorities outlined in the Arizona Cancer Control Plan. These priorities include prevent cancer, detect cancer early, elevate cancer treatment, galvanize quality of life/survivorship care networks, and catalyze research. Susan G. Kamen速 Central and Northern Arizona is one of 120 Affiliates around the world dedicated to combating breast cancer at every front. Its service area encompasses all of central and northern Arizona, including Apache, Coconino, Gila, La Paz, Maricopa, Mohave, Navajo, Pinal and Yavapai counties. Through events like the Susan G. Kamen Phoenix Race for the Cure速, the Affiliate has invested more than $26.4 million in local breast health and breast cancer awareness projects in central and northern Arizona, and breast cancer research. This summit served as a forum for clinicians, nurses, program planners, and public health professionals within Commission on Cancer (CoC) accredited hospitals to learn about survivorship care plans and address the implementation of standard 3.3 of CoC accreditation.
Survivorship Care and Care Plans: Transforming Challenges into Opportunities from Carevive
]]> 1403 11 https://cdn.slidesharecdn.com/ss_thumbnails/strickeretalscpsintheusarizonaccv3-150618183604-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Putting it all together: Personalized care for cancer survivors /slideshow/putting-it-all-together-personalized-care-for-cancer-survivors/44510946 astro2014survivorshipcaredelivery-150210123637-conversion-gate01
Presentation made by Dr. Carrie Stricker at American Society for Therapeutic Radiology and Oncology 56th Annual Meeting. Objectives: Identify barriers to the delivery of quality care for post-treatment cancer survivors Identify at least two strategies to overcome these barriers]]>
Presentation made by Dr. Carrie Stricker at American Society for Therapeutic Radiology and Oncology 56th Annual Meeting. Objectives: Identify barriers to the delivery of quality care for post-treatment cancer survivors Identify at least two strategies to overcome these barriers]]> Tue, 10 Feb 2015 12:36:37 GMT /slideshow/putting-it-all-together-personalized-care-for-cancer-survivors/44510946 OnQHealth@slideshare.net(OnQHealth) Putting it all together: Personalized care for cancer survivors OnQHealth Presentation made by Dr. Carrie Stricker at American Society for Therapeutic Radiology and Oncology 56th Annual Meeting. Objectives: Identify barriers to the delivery of quality care for post-treatment cancer survivors Identify at least two strategies to overcome these barriers <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/astro2014survivorshipcaredelivery-150210123637-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presentation made by Dr. Carrie Stricker at American Society for Therapeutic Radiology and Oncology 56th Annual Meeting. Objectives: Identify barriers to the delivery of quality care for post-treatment cancer survivors Identify at least two strategies to overcome these barriers
Putting it all together: Personalized care for cancer survivors from Carevive
]]> 770 6 https://cdn.slidesharecdn.com/ss_thumbnails/astro2014survivorshipcaredelivery-150210123637-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Survivorship Care Plans in the U.S.: Current Status and Future Challenges /slideshow/survivorship-care-plans-in-the-us-current-status-and-future-challenges/44495288 strickeretalscpsintheustokyo2015-150210071339-conversion-gate02
On Q Health's Chief Clinical Officer, Dr. Carrie Tompkins Stricker, gave a presentation on survivorship care plans in Tokyo, Japan during the 1st International Seminar on Cancer Nursing. The seminar theme was "The Role of Cancer Nursing in Improving Quality of Cancer Care: The Current Situation and Outlook for Developments 10 Years from Now". Learn more about survivorship and On Q Health's Care Planning System: http://bit.ly/onqcareplans]]>
On Q Health's Chief Clinical Officer, Dr. Carrie Tompkins Stricker, gave a presentation on survivorship care plans in Tokyo, Japan during the 1st International Seminar on Cancer Nursing. The seminar theme was "The Role of Cancer Nursing in Improving Quality of Cancer Care: The Current Situation and Outlook for Developments 10 Years from Now". Learn more about survivorship and On Q Health's Care Planning System: http://bit.ly/onqcareplans]]> Tue, 10 Feb 2015 07:13:39 GMT /slideshow/survivorship-care-plans-in-the-us-current-status-and-future-challenges/44495288 OnQHealth@slideshare.net(OnQHealth) Survivorship Care Plans in the U.S.: Current Status and Future Challenges OnQHealth On Q Health's Chief Clinical Officer, Dr. Carrie Tompkins Stricker, gave a presentation on survivorship care plans in Tokyo, Japan during the 1st International Seminar on Cancer Nursing. The seminar theme was "The Role of Cancer Nursing in Improving Quality of Cancer Care: The Current Situation and Outlook for Developments 10 Years from Now". Learn more about survivorship and On Q Health's Care Planning System: http://bit.ly/onqcareplans <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/strickeretalscpsintheustokyo2015-150210071339-conversion-gate02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> On Q Health&#39;s Chief Clinical Officer, Dr. Carrie Tompkins Stricker, gave a presentation on survivorship care plans in Tokyo, Japan during the 1st International Seminar on Cancer Nursing. The seminar theme was &quot;The Role of Cancer Nursing in Improving Quality of Cancer Care: The Current Situation and Outlook for Developments 10 Years from Now&quot;. Learn more about survivorship and On Q Health&#39;s Care Planning System: http://bit.ly/onqcareplans
Survivorship Care Plans in the U.S.: Current Status and Future Challenges from Carevive
]]> 1468 4 https://cdn.slidesharecdn.com/ss_thumbnails/strickeretalscpsintheustokyo2015-150210071339-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-OnQHealth-48x48.jpg?cb=1673469737 We can transform cancer care by helping providers, researchers and patients work together to fight cancer. https://www.carevive.com https://cdn.slidesharecdn.com/ss_thumbnails/ispor22podiumpresentation002-230111204252-6cc805a6-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/predictors-of-symptom-worsening-or-improvement-using-remote-patient-reported-outcomes-pro-technology/255287933 Predictors of Symptom ... https://cdn.slidesharecdn.com/ss_thumbnails/keytakeawaysdebamccbsvirtual-210408155710-thumbnail.jpg?width=320&height=320&fit=bounds OnQHealth/amccbs-virtual2021-conference-takeaways-part-2-245922659 AMCCBS Virtual鐃2021 Co... https://cdn.slidesharecdn.com/ss_thumbnails/keytakeawaysamccbsvirtual-210407012735-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/amccbs-virtual2021-conference-takeaways-part-1/245818891 AMCCBS Virtual鐃2021 Co...